CO2019004741A2 - ¬anticuerpos anti–c1s y métodos de uso de los mismos - Google Patents
¬anticuerpos anti–c1s y métodos de uso de los mismosInfo
- Publication number
- CO2019004741A2 CO2019004741A2 CONC2019/0004741A CO2019004741A CO2019004741A2 CO 2019004741 A2 CO2019004741 A2 CO 2019004741A2 CO 2019004741 A CO2019004741 A CO 2019004741A CO 2019004741 A2 CO2019004741 A2 CO 2019004741A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- present
- provides
- methods
- nucleic acids
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 102000016917 Complement C1 Human genes 0.000 abstract 1
- 108010028774 Complement C1 Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona anticuerpos que se enlazan de una forma específica con el componente de la vía del complemento C1s. La presente invención proporciona ácidos nucleicos que comprenden las secuencias de nucleótidos que codifican los anticuerpos anti–C1s; y las células huéspedes que comprenden los ácidos nucleicos. La presente invención proporciona composiciones que comprenden los anticuerpos anti–C1s. La presente invención proporciona los métodos de uso de los anticuerpos anti–C1s.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407390P | 2016-10-12 | 2016-10-12 | |
| PCT/US2017/056349 WO2018071676A1 (en) | 2016-10-12 | 2017-10-12 | Anti-c1s antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019004741A2 true CO2019004741A2 (es) | 2019-07-31 |
Family
ID=61906346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0004741A CO2019004741A2 (es) | 2016-10-12 | 2019-05-08 | ¬anticuerpos anti–c1s y métodos de uso de los mismos |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20200048332A1 (es) |
| EP (1) | EP3525583A4 (es) |
| JP (3) | JP7069138B2 (es) |
| KR (2) | KR20240025715A (es) |
| CN (2) | CN110300520B (es) |
| AR (1) | AR110677A1 (es) |
| AU (2) | AU2017341766A1 (es) |
| BR (1) | BR112019007309A2 (es) |
| CA (1) | CA3040253A1 (es) |
| CL (1) | CL2019000975A1 (es) |
| CO (1) | CO2019004741A2 (es) |
| CR (1) | CR20190223A (es) |
| DO (1) | DOP2019000085A (es) |
| EA (1) | EA201990884A1 (es) |
| EC (1) | ECSP19033211A (es) |
| IL (2) | IL265957B2 (es) |
| MX (1) | MX2019004259A (es) |
| PE (1) | PE20191031A1 (es) |
| PH (1) | PH12019500789A1 (es) |
| SG (1) | SG11201903012RA (es) |
| TN (1) | TN2019000109A1 (es) |
| TW (1) | TWI773695B (es) |
| WO (1) | WO2018071676A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110818798A (zh) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| AU2013337638B2 (en) | 2012-11-02 | 2018-10-25 | Bioverativ Usa Inc. | Anti-complement C1s antibodies and uses thereof |
| WO2016164358A1 (en) | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| BR112022021077A2 (pt) * | 2020-04-20 | 2022-12-13 | Genzyme Corp | Anticorpos humanizados antifator bb de complemento e uso dos mesmos |
| EP4193153A1 (en) * | 2020-08-06 | 2023-06-14 | Bioverativ USA Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
| US11958899B2 (en) | 2021-07-13 | 2024-04-16 | Mabwell Therapeutics Inc. | Anti-C1s antibodies and uses thereof |
| WO2023245048A1 (en) | 2022-06-15 | 2023-12-21 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| US20240025978A1 (en) | 2022-06-24 | 2024-01-25 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP0648271B1 (en) | 1991-08-20 | 2003-04-16 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| WO1994012649A2 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| ATE304604T1 (de) | 1993-06-24 | 2005-09-15 | Frank L Graham | Adenovirus vektoren für gentherapie |
| SK283703B6 (sk) | 1993-10-25 | 2003-12-02 | Canji, Inc. | Rekombinantný adenovírusový vektor a jeho použitie |
| WO1996017951A2 (en) | 1994-12-09 | 1996-06-13 | Rpms Technology Limited | Identification of genes responsible for in vivo survival of microorganisms |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| ES2153654T3 (es) | 1996-10-17 | 2001-03-01 | Oxford Biomedica Ltd | Vectores retrovirales. |
| GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB9622500D0 (en) | 1996-10-29 | 1997-01-08 | Oxford Biomedica Ltd | Therapeutic gene |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| US7271002B2 (en) | 2001-11-09 | 2007-09-18 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| US7657380B2 (en) * | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| US9715692B1 (en) | 2003-04-11 | 2017-07-25 | Facebook, Inc. | System for managing bids for pay-per-click search engines |
| PT1737891E (pt) * | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP5193600B2 (ja) | 2005-07-05 | 2013-05-08 | 株式会社カネカ | メタクリル系樹脂組成物 |
| FR2897868B1 (fr) * | 2006-02-24 | 2012-08-31 | Lab Francais Du Fractionnement | Anticorps anti-idiotypiques neutralisant l'activite inhibitrice d'un anticorps inhibiteur dirige contre le domaine c1 du facteur viii. |
| KR101589259B1 (ko) | 2006-06-21 | 2016-02-01 | 유니큐어 아이피 비.브이. | 곤충세포 내 ａａｖ의 생산에 유용한 ａａｖ-ｒｅｐ78의 번역을 위한 변형된 개시 코돈을 갖는 벡터 |
| WO2009020640A2 (en) * | 2007-08-08 | 2009-02-12 | Swarmcast, Inc. | Media player plug-in installation techniques |
| CA3053156A1 (en) | 2008-12-03 | 2010-06-10 | Genmab A/S | Antibody variants having modifications in the constant region |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| CA3049237C (en) | 2010-04-23 | 2024-06-11 | University Of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| CN110818798A (zh) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| AU2013337638B2 (en) | 2012-11-02 | 2018-10-25 | Bioverativ Usa Inc. | Anti-complement C1s antibodies and uses thereof |
| AU2014213147B2 (en) * | 2013-01-31 | 2019-01-17 | lmmunAbs Inc. | C5 antibody and method for preventing and treating complement-related diseases |
| CA2913318C (en) | 2013-05-23 | 2024-03-26 | Broteio Pharma B.V. | Binding molecules that bind human complement factor c2 and uses thereof |
| FI3019240T3 (fi) | 2013-07-09 | 2024-05-30 | Annexon Inc | Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä |
| WO2016164358A1 (en) * | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
-
2017
- 2017-10-12 IL IL265957A patent/IL265957B2/en unknown
- 2017-10-12 JP JP2019519690A patent/JP7069138B2/ja active Active
- 2017-10-12 IL IL308156A patent/IL308156A/en unknown
- 2017-10-12 EP EP17859451.1A patent/EP3525583A4/en active Pending
- 2017-10-12 MX MX2019004259A patent/MX2019004259A/es unknown
- 2017-10-12 AR ARP170102855A patent/AR110677A1/es unknown
- 2017-10-12 WO PCT/US2017/056349 patent/WO2018071676A1/en unknown
- 2017-10-12 BR BR112019007309A patent/BR112019007309A2/pt unknown
- 2017-10-12 CR CR20190223A patent/CR20190223A/es unknown
- 2017-10-12 CN CN201780074920.XA patent/CN110300520B/zh active Active
- 2017-10-12 KR KR1020247005368A patent/KR20240025715A/ko active Application Filing
- 2017-10-12 EA EA201990884A patent/EA201990884A1/ru unknown
- 2017-10-12 SG SG11201903012RA patent/SG11201903012RA/en unknown
- 2017-10-12 CN CN202211195613.6A patent/CN116554320A/zh active Pending
- 2017-10-12 KR KR1020197013448A patent/KR102638884B1/ko active IP Right Grant
- 2017-10-12 TN TNP/2019/000109A patent/TN2019000109A1/en unknown
- 2017-10-12 AU AU2017341766A patent/AU2017341766A1/en not_active Abandoned
- 2017-10-12 PE PE2019000814A patent/PE20191031A1/es unknown
- 2017-10-12 US US16/340,991 patent/US20200048332A1/en not_active Abandoned
- 2017-10-12 CA CA3040253A patent/CA3040253A1/en active Pending
- 2017-10-12 TW TW106134895A patent/TWI773695B/zh active
-
2019
- 2019-04-08 DO DO2019000085A patent/DOP2019000085A/es unknown
- 2019-04-11 PH PH12019500789A patent/PH12019500789A1/en unknown
- 2019-04-11 CL CL2019000975A patent/CL2019000975A1/es unknown
- 2019-05-08 CO CONC2019/0004741A patent/CO2019004741A2/es unknown
- 2019-05-10 EC ECSENADI201933211A patent/ECSP19033211A/es unknown
-
2022
- 2022-04-28 JP JP2022073972A patent/JP7420864B2/ja active Active
- 2022-07-12 AU AU2022205174A patent/AU2022205174A1/en active Pending
-
2023
- 2023-07-07 US US18/349,027 patent/US20240076363A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002216A patent/JP2024038319A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004741A2 (es) | ¬anticuerpos anti–c1s y métodos de uso de los mismos | |
| BR112017003582A2 (pt) | anticorpos, composições e usos | |
| CO2017000300A2 (es) | Moléculas con especificidad para cd45 y cd79 | |
| CO2017011238A2 (es) | Anticuerpos anti-c1s humanizados | |
| SV2018005619A (es) | Composiciones de oligonucleotidos y metodos de los mismos | |
| CY1124663T1 (el) | Αντιιικα παραγωγα ν4-υδροξυκυτιδινης | |
| CL2019000259A1 (es) | Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584) | |
| CO2018000976A2 (es) | Constructos de anticuerpo para cd70 y cd3 | |
| CO2017012562A2 (es) | Vectores virales adenoasociados que codifican para la enzima iduronato-2-sulfatasa | |
| CO2020005981A2 (es) | Anticuerpos anti-tau y uso de los mismos | |
| BR112019012343A2 (pt) | anticorpos il-11ra | |
| CO2017000228A2 (es) | Moléculas con especificidad para cd79 y cd22 | |
| BR112018004965A2 (pt) | domínios de superfamìlia de imunoglobulina variante ajustàvel | |
| CO2017011546A2 (es) | Adhesivos acrílicos en emulsión | |
| DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
| BR112017009792A2 (pt) | anticorpos anti-pdgf-b e métodos de uso | |
| CR20170518A (es) | Neutralización del virus chikungunya mediada por anticuerpos. | |
| ES2974905T3 (es) | Composiciones, kits y métodos para inducir citorresistencia adquirida mediante el uso de inductores de proteínas de estrés | |
| UY35718A (es) | Anticuerpos anti-csf-1r: métodos de expresión de los mismos. | |
| AR096236A1 (es) | Anticuerpos de dominio simple vhh dirigidos a norovirus gi.1 y gii.4 y sus usos | |
| BR112016030129A2 (pt) | Composição, artigo moldado por injeção e processo para produzir um artigo moldado por injeção | |
| CL2018001279A1 (es) | Spodoptera frugiperda resistente a vip3a. | |
| WO2014145870A3 (en) | Novel compositions, methods and kits for blood typing | |
| CL2017003311A1 (es) | Proteínas de fijación multiespecífica. | |
| CL2017001383A1 (es) | Proceso para la fabricación de anhídrido carboxílico |